Background Despite PD-L1 (Programmed death receptor ligand-1) expression on tumor cells and cytotoxic T lymphocytes tumor infiltration in the tumor microenvironment, human pancreatic cancer stands out as one of the human cancers that does not respond to immune checkpoint inhibitor (ICI) immunotherapy. Epigenome dysregulation has emerged as a major mechanism in T cell exhaustion and non-response to ICI immunotherapy, we, therefore, aimed at testing the hypothesis that an epigenetic mechanism compensates PD-L1 function to render pancreatic cancer non-response to ICI immunotherapy.Methods Two orthotopic pancreatic tumor mouse models were used for chromatin immunoprecipitation-Seq and RNA-Seq to identify genome-wide dysregulation of H3K4me3 and...
Background: WD repeat domain 3 (WDR3) is involved in a variety of cellular processe...
Abstract Background Dysregulated expression and activation of receptor tyrosine kinases (RTKs) are a...
Pancreatic ductal adenocarcinoma (PDAC) is the most common type of pancreatic cancer. PDAC is one of...
Background: Pancreatic cancer is one of the cancers where anti-PD-L1/PD-1 immunotherapy has been uns...
The study by Gonda and colleagues, in this issue of Cancer Research, represents the first combinator...
Abstracts Background Pancreatic ductal adenocarcinoma is one of the leading causes of cancer-related...
INTRODUCTION: Pancreatic ductal adenocarcinoma (PDA) has the worst prognosis among cancers, mainly d...
Despite recent advances in cancer treatment, resistance to therapy and metastatic progression remain...
Compared to pancreatic adenocarcinoma (PDAC), pancreatic neuroendocrine tumors (PanNET) represent a ...
Pancreatic ductal adenocarcinoma (PDA) is the third leading cause of cancer related death, with a fi...
Pancreatic cancer remains deadly. High mortality is attributable to the inability to detect this can...
SummaryCurrent treatment regimens for pancreatic ductal adenocarcinoma (PDAC) yield poor 5-year surv...
Current treatment regimens for pancreatic ductal adenocarcinoma (PDAC) yield poor 5-year survival, e...
Programmed cell death protein 1(PD-1) is a type of immune-inhibitory checkpoint protein, which deliv...
Objective: Pancreatic cancer is a leading cause of cancer-related death in the Western world. Curren...
Background: WD repeat domain 3 (WDR3) is involved in a variety of cellular processe...
Abstract Background Dysregulated expression and activation of receptor tyrosine kinases (RTKs) are a...
Pancreatic ductal adenocarcinoma (PDAC) is the most common type of pancreatic cancer. PDAC is one of...
Background: Pancreatic cancer is one of the cancers where anti-PD-L1/PD-1 immunotherapy has been uns...
The study by Gonda and colleagues, in this issue of Cancer Research, represents the first combinator...
Abstracts Background Pancreatic ductal adenocarcinoma is one of the leading causes of cancer-related...
INTRODUCTION: Pancreatic ductal adenocarcinoma (PDA) has the worst prognosis among cancers, mainly d...
Despite recent advances in cancer treatment, resistance to therapy and metastatic progression remain...
Compared to pancreatic adenocarcinoma (PDAC), pancreatic neuroendocrine tumors (PanNET) represent a ...
Pancreatic ductal adenocarcinoma (PDA) is the third leading cause of cancer related death, with a fi...
Pancreatic cancer remains deadly. High mortality is attributable to the inability to detect this can...
SummaryCurrent treatment regimens for pancreatic ductal adenocarcinoma (PDAC) yield poor 5-year surv...
Current treatment regimens for pancreatic ductal adenocarcinoma (PDAC) yield poor 5-year survival, e...
Programmed cell death protein 1(PD-1) is a type of immune-inhibitory checkpoint protein, which deliv...
Objective: Pancreatic cancer is a leading cause of cancer-related death in the Western world. Curren...
Background: WD repeat domain 3 (WDR3) is involved in a variety of cellular processe...
Abstract Background Dysregulated expression and activation of receptor tyrosine kinases (RTKs) are a...
Pancreatic ductal adenocarcinoma (PDAC) is the most common type of pancreatic cancer. PDAC is one of...